Evidence map›Paper›PMID 37865406›Full record

ArticleBMJ open2023

Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children.

Ugonna T Offor, Paolo Hollis, Milos Ognjanovic, Gareth Parry, Abbas Khushnood, Heather M Long, Andrew R Gennery, Chris M Bacon, Jacob Simmonds, Zdenka Reinhardt and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Ugonna T OfforWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK ugo.offor@newcastle.ac.uk.ORCID 0000-0002-7207-3175
Paolo HollisDepartment of Cardiothoracic Transplant, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Milos OgnjanovicDepartment of Paediatric Nephrology, Great North Children's Hospital, Newcastle Upon Tyne, UK.
Gareth ParryDepartment of Cardiopulmonary Transplantation, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Abbas KhushnoodDepartment of Cardiopulmonary Transplantation, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Heather M LongInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Andrew R GenneryTranslational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.
Chris M BaconWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.
Jacob SimmondsDepartment of Cardiothoracic Transplant, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Zdenka ReinhardtDepartment of Cardiopulmonary Transplantation, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Simon BomkenWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.
Newcastle upon Tyne Hospitals NHS Foundation Trust · GBClinical Research Institute · USGreat Ormond Street Hospital for Children NHS Foundation Trust · GBGreat North Children's Hospital · GBInstitute of Immunology · HR

Funding

Medical Research Council MR/S021590/1
6 · The paper itself

Abstract

introductionPaediatric heart transplant patients are disproportionately affected by Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) compared with other childhood solid organ recipients. The drivers for this disparity remain poorly understood. A potential risk factor within this cohort is the routine surgical removal of the thymus-a gland critical for the normal development of T-lymphocyte-mediated antiviral immunity-in early life, which does not occur in other solid organ transplant recipients. Our study aims to describe the key immunological differences associated with early thymectomy, its impact on the temporal immune response to EBV infection and subsequent risk of PTLD. METHODS AND ANALYSIS: Prospective and sequential immune monitoring will be performed for 34 heart transplant recipients and 6 renal transplant patients (aged 0-18 years), stratified into early (<1 year), late (>1 year) and non-thymectomy groups. Peripheral blood samples and clinical data will be taken before transplant and at 3, 6, 12 and 24 months post-transplant. Single cell analysis of circulating immune cells and enumeration of EBV-specific T-lymphocytes will be performed using high-dimensional spectral flow cytometry with peptide-Major Histocompatibilty Complex (pMHC) I/II tetramer assay, respectively. The functional status of EBV-specific T-lymphocytes, along with EBV antibodies and viral load will be monitored at each of the predefined study time points. ETHICS AND DISSEMINATION: Ethical approval for this study has been obtained from the North of Scotland Research Ethics Committee. The results will be disseminated through publications in peer-reviewed journals, presentations at scientific conferences and patient-centred forums, including social media. TRIAL REGISTRATION NUMBER: ISRCTN10096625.

Indexed as

Epstein-Barr Virus InfectionsHeart TransplantationLymphoproliferative DisordersChildHerpesvirus 4, HumanHumansImmunologic FactorsObservational Studies as TopicProspective StudiesRisk FactorsThymectomyUnited KingdomViral LoadImmunologic FactorsIMMUNOLOGYLymphomaObservational StudyPaediatric oncologyPaediatric transplant surgeryRisk Factors

Identifiers

PMID37865406
PMCPMC10603490
OpenAlexW4387849975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.